Mismatch Repair Deficiency Secondary to MLH1 Methylation is Associated with Worse Recurrence-Free and Overall Survival in Endometrioid-Type Endometrial Cancer

被引：0
作者：
Avila, Monica [1 ]
Fellman, Bryan [2 ]
Broaddus, Russell [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Bellaire, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
MODERN PATHOLOGY | 2019年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1002
引用
收藏
页数：2
相关论文
共 28 条
  • [21] Tumor Mismatch Repair Immunohistochemistry and DNA MLH1 Methylation Testing of Patients With Endometrial Cancer Diagnosed at Age Younger Than 60 Years Optimizes Triage for Population-Level Germline Mismatch Repair Gene Mutation Testing
    Buchanan, Daniel D.
    Tan, Yen Y.
    Walsh, Michael D.
    Clendenning, Mark
    Metcalf, Alexander M.
    Ferguson, Kaltin
    Arnold, Sven T.
    Thompson, Bryony A.
    Lose, Felicity A.
    Parsons, Michael T.
    Walters, Rhiannon J.
    Pearson, Sally-Ann
    Cummings, Margaret
    Oehler, Martin K.
    Blomfield, Penelope B.
    Quinn, Michael A.
    Kirk, Judy A.
    Stewart, Colin J.
    Obermair, Andreas
    Young, Joanne P.
    Webb, Penelope M.
    Spurdle, Amanda B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (02) : 90 - +
  • [22] CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients
    Meller, Sebastian
    Zipfel, Lisa
    Gevensleben, Heidrun
    Dietrich, Joern
    Ellinger, Joerg
    Majores, Michael
    Stein, Johannes
    Sailer, Verena
    Jung, Maria
    Kristiansen, Glen
    Dietrich, Dimo
    EPIGENETICS, 2016, 11 (12) : 871 - 880
  • [23] Enrichment of chromosome 1 and 6p21 genes associated with worse progression-free and overall survival in endometrial cancer patients
    Challa, Rusheeswar
    Chandramouli, G. V. R.
    Fedorko, Alyssa
    Conrads, Thomas P.
    Risinger, John I.
    CANCER RESEARCH, 2015, 75
  • [24] Beyond mismatch repair deficiency? Pre-treatment neutrophil-to-lymphocyte ratio is associated with improved overall survival in patients with recurrent endometrial cancer treated with immunotherapy
    Barrington, David A.
    Calo, Corinne
    Baek, Jae
    Brown, Morgan
    Wagner, Vincent
    Gonzalez, Lynette
    Huffman, Allison
    Benedict, Jason
    Bixel, Kristin
    GYNECOLOGIC ONCOLOGY, 2022, 166 (03) : 522 - 529
  • [25] Beyond mismatch repair deficiency? Pre-treatment neutrophil-to-lymphocyte ratio is associated with improved overall survival in patients with recurrent endometrial cancer treated with immunotherapy
    Baek, Jae
    Brown, Morgan
    Barrington, David
    Calo, Corinne
    Wagner, Vincent
    Gonzalez, Lynette
    Huffman, Allison
    Benedict, Jason
    Bixel, Kristin
    GYNECOLOGIC ONCOLOGY, 2022, 165 : S1 - S2
  • [26] Is there an Advantage of Lymphadenectomy for Overall and Recurrence-Free Survival in Endometrial Carcinoma Type I FIGO IB G1-2? A Retrospective Population-Based Cohort Analysis
    Hassas, Dunja
    Papathemelis, Thomas
    Gerken, Michael
    Scharl, Sophia
    Scharl, Anton
    Lux, Michael P.
    Beckmann, Mathias W.
    Ortmann, Olaf
    Klinkhamtner-Schalke, Monika
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 90 - 90
  • [27] Is there a benefit of lymphadenectomy for overall and recurrence-free survival in type I FIGO IB G1-2 endometrial carcinoma? A retrospective population-based cohort analysis
    Thomas Papathemelis
    Dunja Hassas
    Michael Gerken
    Monika Klinkhammer-Schalke
    Anton Scharl
    Michael P. Lux
    Mathias W. Beckmann
    Sophia Scharl
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 2019 - 2027
  • [28] Is there a benefit of lymphadenectomy for overall and recurrence-free survival in type I FIGO IB G1-2 endometrial carcinoma? A retrospective population-based cohort analysis
    Papathemelis, Thomas
    Hassas, Dunja
    Gerken, Michael
    Klinkhammer-Schalke, Monika
    Scharl, Anton
    Lux, Michael P.
    Beckmann, Mathias W.
    Scharl, Sophia
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (10) : 2019 - 2027
123